STOCKS TELEGRAPH

Tag: Aptose Biosciences

  • Aptose Biosciences (APTO) Soars 12.77% Ahead of Clinical Update

    Aptose Biosciences (APTO) Soars 12.77% Ahead of Clinical Update

    Aptose Biosciences Inc. (NASDAQ: APTO) shares have exhibited a remarkable ascent, making a 12.77% increase, closing at $3.18 on Friday in the regular trading. This surge in Aptose Biosciences’ stock this session value is attributed to the impending release of a clinical update scheduled for Monday, October 30, 2023.

    The forthcoming clinical update from APTO will coincide with poster presentations at the esteemed European School of Haematology (ESH) 6th International Conference, taking place from October 29 to 31, 2023, in the picturesque locale of Estoril, Portugal. The featured poster is entitled “Acute Myeloid Leukemia: Molecular and Translational Advances in Biology and Treatment.”

    This webcast event promises a comprehensive overview of the most recent clinical data pertaining to Aptose’s lead compound, tuspetinib. Notably, it will showcase the insights of Dr. Naval Daver, MD, who holds the position of Professor and is the Director of the Leukemia Research Alliance Program within the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, TX.

    Dr. Daver serves as the principal investigator for Aptose’s APTIVATE trial and has gained recognition for his substantial contributions to the development of innovative treatments for acute myeloid leukemia (AML), including various combination therapies. Tuspetinib, when administered as a monotherapy, has demonstrated a commendable level of tolerability and remarkable efficacy in a diverse group of patients afflicted with relapsed or refractory (R/R) AML.

    Impressively, it yielded a 42% complete response or complete response with partial hematologic recovery (CR/CRh) rate among assessable patients who had not previously been exposed to venetoclax (VEN). Furthermore, the APTIVATE international Phase 1/2 expansion trial is currently investigating the combination of tuspetinib with venetoclax (VEN) in R/R AML patients.

    This combination, known as the TUS/VEN doublet, has been well-tolerated and has delivered multiple positive responses in patients who had previously failed venetoclax, including those who had experienced prior failures with FLT3 inhibitors. This patient cohort represents an emerging demographic with substantial unmet medical needs.

    Aptose Biosciences is also scheduled to release its financial results for the third quarter ending on September 30, 2023, for Thursday, November 9, 2023, after the close of the market. This announcement will be accompanied by a corporate update.

  • Aptose Biosciences Inc. (APTO) stock continues to Tumble Despite Promising Results of its Under-Study Product

    Aptose Biosciences Inc. (APTO) stock fell by a further 13% in the premarket, at $1.69 on December 14. The stock’s movement seems unaffected by the promising results of APTO’s HM43239.

    In last trading, the stock moved between $1.87 and $1.9972, closing at $1.9500, with a 2.01% decrease.

    Aptose Biosciences Inc. (APTO) is a clinical-stage biotech company targeting oncological needs. Currently, its 88.95 million outstanding shares trade at a market capitalization of $177.73 million.

    APTO’s HM43239

    On December 13, the company reported the promising activity of its HM43239 oral myeloid kinome inhibitor (MKI). The HM43239 showed durable single-agent activity in relapsed or refractory AML patients. Moreover, the company presented the data at the 2021 American Society of Hematology (ASH) Annual Meeting on Monday.

    The HM43239 is a very potent MKI that targets key kinases operative in myeloid malignancies. Further, in its ongoing international Phase ½ study, HM4329 not only delivered multiple complete responses but also clinical benefits.

    In addition, the company also presented its clinical data for luxeptinib and APTO-253 in the meeting. According to the Phase ½ studies, luxeptinib was generally well tolerated at various dosages.

    Previous News on the HM43239

    On November 04, APTO announced its exclusive worldwide agreement with Hanmi Pharmaceuticals for HM43239. Hanmi Pharmaceuticals, which is a South Korean company gave exclusive rights to APTO for all indications of the MKI.

    As per the agreement, APTO paid $12.5 million as upfront payment to Hanmi. This included cash of $5 million and APTO shares of $7.5 million. Moreover, a further $407.5 million will paid in future milestone payments that are subject to certain conditions. In addition, Hanmi will also receive tiered royalties on net sales.

    APTO’s Q3 Earnings

    On November 11, the company declared its financial results for the third quarter of 2021. As per the financial results, APTO incurred a net loss of $11.3 million in the third quarter of 2021. This compares to a net loss of $13.2 million in the same quarter of 2020. Subsequently, the net loss per share was $0.13 in the Q3 of 2021, against $0.15 in Q3 of 2020.

    Moreover, on September 30, 2021, the cash, cash equivalents, and investments totaled $95.1 million. Based on this, the company expects a cash runway through early 2023, for all operations and research & development.

  • Aptose Biosciences Inc. (NASDAQ: APTO) stock value slides in the premarket trading

    Aptose Biosciences Inc. (NASDAQ: APTO) share were dipping -25.65% to 4.55 in the premarket trading after the company released highlights from a business update, In conjunction with attendance at the 2020 Annual Meeting of the American Society of Hematology (ASH) event held on Sunday, December 6th,

    The current clinical status of CG-806, Aptose oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor has been evaluated by the Aptose management team in two phases 1 a/b trial, one in patients with refractory acute myeloid leukemia (AML) and the other in patients with relapsed or refractory B-cell malignancies. The committee has also evaluated the clinical status of acute myeloid leukemia (AML) (MDS).